Lavilla Olleros, 14,921 patient HCQ late treatment study: 36% lower mortality [p<0.0001] https://c19p.org/lavillaolleros
copied to clipboard
Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19
et al., PLOS ONE, doi:10.1371/journal.pone.0261711
Retrospective 14,921 hospitalized patients in Spain, showing lower mortality with HCQ treatment.
|
risk of death, 36.2% lower, RR 0.64, p < 0.001, treatment 2,285 of 12,772 (17.9%), control 774 of 2,149 (36.0%), NNT 5.5, adjusted per study, odds ratio converted to relative risk, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lavilla Olleros et al., 1/21/2022, retrospective, Spain, Europe, peer-reviewed, 22 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.